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Background: The fixed triple combination Beclometasone dipropionate/Formoterol fuma-
rate/Glycopyrronium (BDP/FF/G, Trimbow®), an extrafine formulation in a unique pressur-
ized metered dose inhaler, is indicated for the maintenance treatment in adult patients with 
moderate to severe COPD, not adequately treated by ICS/LABA or LABA/LAMA. 
Besides the evidence from three randomized controlled trials, the impact of fixed triple 
therapy has not been extensively evaluated in a real-world population of COPD patients. 
TRITRIAL (TRIple Therapy in Real life: Impact on Adherence and HeaLth status) is a non- 
interventional study to assess the effect of BDP/FF/G in a real world setting in Italy.
Design: TRITRIAL is a 12-month, multicenter, cohort, prospective, longitudinal observational 
study. Two follow-up visits will be performed at 6 and 12 months, respectively. The study 
includes the collection of anamnestic clinical and functional data before the start of BDP/FF/G. 
The study is built for digital conduction, from signature of the informed consent on a dedicated 
web platform, to the collection of questionnaires and clinical data on the eCRF.
Population: A total of 800 patients with COPD ranging from Global Initiative for 
Obstructive Lung Disease (GOLD) stages 2 to 4, receiving therapy with BDP/FF/G accord-
ing to the Summary of Product Characteristics and local clinical practice, will be recruited. 
All concomitant therapies will be permitted for the duration of the study.
Evaluations: The primary endpoint is the change of CAT score at 12 months versus 
baseline. Secondary endpoints are adherence, health-related quality of life, sleep quality, 
disease-related outcomes (lung function and COPD exacerbations), device usability, eco-
nomic resources consumption, and safety.
Conclusion: TRITRIAL study is expected to give relevant information about effectiveness 
of BDP/FF/G fixed triple therapy in a real-life setting of patients with COPD, where 
adherence, usability of inhalers and patient’s preference of the device are crucial factors 
for the success of the therapy.
Keywords: COPD, symptoms, health status, adherence, LAMA, LABA, ICS
Introduction
Triple therapy is widely prescribed to COPD patients in clinical practice, as a step- 
up treatment for patients who remain symptomatic and/or continue to experience 
exacerbations despite maintenance therapy, commonly using two separate inhalers. 
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A recent review from the United Kingdom showed that, 
from 2004 to 2009, the use of triple therapy in general 
practice increased from 25% to 59% for patients with very 
severe COPD, from 17% to 45% for severe COPD and 
from 7% to 21% for mild COPD patients, based on lung 
function assessment.1 Furthermore, in a study conducted 
on an Italian database of General Practitioners, 21% of 
patients with COPD were prescribed a triple therapy over 
a period of 4.5 years.2 Nonetheless, while its use has 
increased, relatively few studies have been correctly con-
ducted to test the efficacy of triple therapy, administered 
by separate inhalers, compared to ICS/LABA, LABA/ 
LAMA or LAMA in terms of preventing exacerbations. 
The fixed triple combination Beclometasone dipropionate/ 
Formoterol fumarate/Glycopyrronium (BDP/FF/G, 
Trimbow®, Chiesi Farmaceutici) in an extrafine formula-
tion and a unique pressurized metered dose inhaler 
(pMDI), has been granted market authorization from the 
European Commission and the Italian Agency (AIFA) for 
the maintenance treatment in adult patients with moderate 
to severe COPD, who are not adequately treated by 
a combination of an ICS and a LABA or by 
a combination of a LABA and a LAMA (but this latter 
extension of indication is not yet reimbursed by AIFA). 
BDP/FF/G was developed through a clinical program con-
sisting of 18 trials with more than 8,000 patients recruited. 
Three large Phase III studies, ie, the TRILOGY,3 
TRINITY,4 and TRIBUTE,5 showed that BDP/FF/G fixed 
triple combination is superior to ICS/LABA, to LAMA 
monotherapy, and to LABA/LAMA in terms of lung func-
tion and exacerbation prevention in COPD patients with 
history of previous exacerbations. In these studies BDP/ 
FF/G also showed relevant and consistent improvement of 
the quality of life, assessed by the Saint George 
Respiratory Questionnaire (SGRQ). BDP/FF/G is an extra-
fine formulation with a mass median aerodynamic dia-
meter (MMAD) <2 μm,6 designed to reach both large 
and small airways,7 defined as peripheral airways having 
a diameter < 2 mm.8 Despite being considered a “silent 
zone” of the respiratory tract, impairment of small air-
ways, a condition known as small airway dysfunction 
(SAD), has a key role in the pathogenesis of COPD and 
it is considered a functional hallmark of the disease. 
Indeed, in patients with COPD, inflammation is localized 
predominantly in small airways, and conventional inhaled 
therapies (bronchodilators and ICS medications) may not 
reach a good deposition in small airways.9 As demon-
strated by Hogg et al, progression of airflow obstruction 
in COPD is strongly associated with thickening of the 
small airways’ walls and with the presence of inflamma-
tory cells (mostly polymorphonuclear leukocytes and 
macrophages) and lymphocytes.10 Furthermore, the degree 
of abnormalities in small airways (ie, luminal occlusion 
with mucus plugs) is associated with early death in 
patients with COPD and severe emphysema.11 Thus, extra-
fine formulations such as BDP/FF/G, may have the poten-
tial to treat small airways impairment and thus contribute 
to improve disease outcomes. Unfortunately, the damage 
in small airways is not detectable with a standard spiro-
metric assessment, unless in late stages of the disease, 
when the number of airways involved by the pathologic 
process is high.8 In a recent study by Crisafulli et al, 
a strong relationship between SAD and COPD 
Assessment Test (CAT) score was demonstrated, reflecting 
high impact of SAD also on health status in COPD 
patients.12 CAT can easily be used in routine daily clinical 
practice to assess the impact of COPD symptoms on the 
risk of developing serious exacerbations of the disease, 
and thus may help in a clinical setting to match the 
patient’s therapy more closely to individual needs, as it 
also reflects the contribution of SAD to the disease. As the 
CAT is an instrument that measures not only the respira-
tory symptom burden of COPD, but also the general health 
status of patients in daily practice (ie, lack of energy or 
sleep disturbances, limitations in doing activities at home 
or confidence leaving home), it can be considered as 
a measure of health-related quality of life (HRQoL) in 
general.13 Heterogeneity of airway constriction, particu-
larly the increase in peripheral resistance (measured with 
impulse oscillometry) contributes to the circadian varia-
bility of respiratory symptoms. Higher values of peripheral 
resistance, which is a key feature of SAD, are significantly 
associated with worse sleep disorders.14 The COPD and 
Asthma Sleep Impact Scale (CASIS) is a validated ques-
tionnaire which evaluates sleep impairment associated 
with obstructive pulmonary diseases. It comprises 5 
items related to trouble falling asleep in the night or 
staying awake during the day, whereas 2 items specifically 
investigate sleep quality. Higher scores reflect greater 
sleep deterioration in the previous week.15 This test 
could be useful to identify patients with higher risk of 
worse outcomes, as sleep disturbances, especially noctur-
nal dyspnea, are associated with an increased risk of 
exacerbations and mortality.16 As previously said, BDP/ 
FF/G is an extrafine formulation, administered twice daily 
to grant sustained bronchodilation throughout the day and 
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night, and therefore may counteract the impact of morning 
and nocturnal symptoms and sleep disturbances (which are 
common in patients with COPD) on HRQoL. Another 
fundamental requirement to achieve COPD treatment 
goals is adherence. Non-adherence to medications is very 
common in COPD patients, especially when multiple 
inhaled therapies become necessary.17 This is usually the 
case for patients more severely affected by COPD, thus 
forming a vicious cycle of disease worsening and non- 
adherence to treatment. Adherence is a multifactorial con-
struct, that documents how compliant the patient is to 
medical instructions (compliance) but also considers 
social, anamnestic and health economic factors like: phy-
sician-patient-interaction, medical care, patient training on 
correct inhalation, efficacy, satisfaction with therapy and 
tolerability of the therapy.18 The Test of Adherence to 
Inhalers (TAI) is a validated 12-item questionnaire 
designed to evaluate adherence to inhaled therapy in 
COPD and asthmatic patients by the recognition of differ-
ent behavioral patterns of non-adherence. It is a simple and 
reliable tool that comprises a patient domain (items from 1 
to 10) and a physician domain (items 11 and 12).19 The 
adherence measurement and documentation of reasons for 
non-adherence are more reliable in non-interventional stu-
dies compared to clinical trials, as they better reflect the 
patient’s daily life. In a recent retrospective study on 
General Practice in Italy, 85% of enrolled patients with 
COPD showed poor adherence to free triple inhaled ther-
apy, and poor adherence was associated with the presence 
of comorbidities (heart failure, depression, peripheral vas-
cular disease) which are common in those with COPD.20 
Furthermore, patients with COPD often need to use multi-
ple inhalers as part of their therapy, which require different 
inhalation techniques. Thus, the use of one single inhaler 
device that combines all required compounds for bronch-
odilation and anti-inflammatory effects may greatly facil-
itate and improve the usability that in turn might result into 
improved clinical outcomes. Despite the evidence from 
regulatory trials, the effects of fixed BDP/FF/G combina-
tion on patients’ HRQoL, adherence and clinical outcomes 
have not been extensively assessed on a real-world COPD 
population. The TRIple Therapy in Real life: Impact on 
Adherence and HeaLth status (TRITRIAL) Study 
(ClinicalTrials.gov No. NCT03963167) is a non- 
interventional study with the aim to assess the effect of 
treatment with BDP/FF/G on health status, HRQoL and 
adherence in a real-world setting of COPD patients in 
Italy. A groundbreaking aspect of this study is the use of 
patient reported outcomes (PROs) collected through elec-
tronically validated questionnaires on a dedicated web 
platform available for PCs, tablets, and smartphones. 
Also the informed consent to the study is collected through 
an electronic procedure, where all the aspects of the study 
will be ruled out with patients step by step, before signing 
the document.
Patients and Methods
Study Design and Population
TRITRIAL study is a multicenter, cohort, prospective 
observational study. COPD patients who have been pre-
scribed BDP/FF/G fixed combination will be recruited and 
observed for 12 months, as per routine local clinical prac-
tice. The study plan includes a brief retrospective phase, 
consisting of data of assessments performed at time of 
initiation of BDP/FF/G, which are going to be collected 
at the baseline visit (Visit 1), and a prospective phase that 
will include two follow-up visits, after 6±1 months 
(Visit 2) and 12±1 months (Visit 3) of treatment with 
BDP/FF/G. In case of premature withdrawal from the 
study for whatever reason, subjects should undergo an 
“Early termination Visit”. The investigational plan is sum-
marized in Figure 1. The overall study duration from first 
patient enrolled to the last patient completed is expected to 
be about 30 months, based on an expected 18-month 
period for recruitment and a 12-month follow-up. 
Approximately 720 patients with moderate to very severe 
COPD (Stage 2–4), according to the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) 2019 
Update,21 will take part in the study. The study has been 
approved by all local Ethics Committees (Supplementary 
Materials). Currently, the enrollment is ongoing and 
patients will be recruited in 50 Respiratory Medicine 
Centers (RMC) in Italy. Patients must meet all the follow-
ing inclusion criteria to be eligible for enrollment into the 
study: male or female aged ≥ 40 years; COPD assessment 
test (CAT) score >10 at the start of BDP/FF/G fixed 
combination; history of at least 1 moderate or severe 
COPD exacerbation during the previous year; patients 
having received prescription and having started treatment 
with BDP/FF/G fixed combination as per local clinical 
practice and according to Trimbow® Summary of 
Product Characteristics (SmPC) within the previous 14 
days. The presence of any of the following criteria will 
exclude a patient from study enrollment: any condition 
and/or illness that might interfere with the study purpose 
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(according to Investigator’s judgement); participation in an 
interventional clinical trial within 30 days prior to enroll-
ment into the present study. Primary objective of the study 
is to evaluate the impact of BDP/FF/G fixed combination 
on health status compared to previous therapy. The pri-
mary endpoint is the change of CAT score from time of 
initiation of BDP/FF/G fixed combination to month 12 (or 
early withdrawal). Secondary objectives are: adherence to 
BDP/FF/G fixed combination, effect on HRQoL and sleep 
quality, disease-related outcomes (eg, lung function and 
COPD exacerbations), economic resources consumption, 
and safety. Primary and secondary endpoints of the study 
are summarized in Figure 2. Health status, adherence, 
quality of life and sleep impairment will be evaluated by 
the administration of electronically validated question-
naires (CAT, TAI, EQ-5D-5L, CASIS) which can be easily 
performed with laptop, tablet or smartphone, reducing 
waste of time and paper. EQ-5D-5L is a simple validated 
questionnaire for assessing quality of life on 5 dimensions 
(mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression) and 5 levels of severity, but also gives 
information about health benefits in terms of quality- 
adjusted life years (QALY).22 Patients’ satisfaction and 
usability of the inhaler device will also be assessed by an 
electronic 8-item questionnaire designed specifically for 
this study. If patients are not able to use electronic tools, 
Figure 1 Investigation schedule of assessments. *Or early withdrawal.
Figure 2 Primary and secondary endpoints of TRITRIAL study. *Or early withdrawal.
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these tests can be administered in paper form. Results of 
laboratory tests (if required by the physician) will be 
registered at any time during the study period, or in the 6 
months prior to enrollment. Participants will be allowed to 
use any concomitant medication if necessary for the treat-
ment of pre-existing concomitant diseases or for intercur-
rent diseases. All concomitant therapies will be permitted 
after clinical evaluation by the Investigator, and data will 
be collected for the whole duration of the study. The use of 
any other therapy for COPD is also allowed, according to 
clinical judgment and the local standard of care. This study 
will be conducted in compliance with the Declaration of 
Helsinki (1964 and amendments), current ICH E6 Good 
Clinical Practices and all other applicable laws and regula-
tions, as applicable to non-interventional studies.
Statistical Analysis
A sample size of 720 subjects was calculated with a paired 
distribution, considering an effect size of 0.144, predicted 
using a minimal clinically important difference of 123 in CAT 
score and a predicted pooled standard deviation of 6.9 – from 
previous studies,3 an alpha level of 0.01 (two-sided) and 
a power of 0.90. However, calculating a 10% dropout, a final 
sample of 800 subjects was established. R statistical analysis 
(version 3.5.2) with pwr package was used to compute the 
sample size. The following analysis set will be considered for 
data analysis: Safety Analysis Set (SAF), consisting of all 
patients enrolled who signed informed consent and 
received at least one administration of BDP/FF/G; Full 
Analysis Set (FAS): consisting of all patients of the SAF who 
have a valid baseline assessment and at least one post-baseline 
evaluation of efficacy, according to an intention-to-treat (ITT) 
principle. The analysis of safety endpoints will be performed in 
the Safety population (SAF). Analysis of efficacy endpoints 
will be performed in the FAS population. The following 
describes the statistical analysis as it was foreseen at the time 
of planning the investigation. All statistical tests will be per-
formed at 0.05 significance level (two-sided). The results of 
efficacy and safety results of the study will be presented in the 
form of descriptive statistics. Continuous variables will be 
summarized by number of cases, mean, standard deviation 
(SD), median, minimum, and maximum. Categorical variables 
will be summarized using counts of patients and percentages. 
Where appropriate, the 95% confidence interval for means and 
percentages will be presented. In case of study discontinuation 
between Month 6 (Visit 2) and Month 12 (Visit 3), the last 
observation carried forward (LOCF) approach will be used to 
address missing data in efficacy endpoints at Month 12 
(Visit 3) or in the Early Termination Visit. No other replace-
ment of missing data will be performed. Demographics and 
baseline variables will be summarized using descriptive statis-
tics for the SAF population. The following variables will be 
summarized and listed: age, gender, race, height, weight, BMI, 
medical history and COPD history (including previous COPD 
exacerbations and hospitalizations), respiratory medications in 
the last 6 months (including the reason for starting BDP/FF/G), 
medications for other non-respiratory diseases in the last 
month, concomitant diseases and concomitant treatments, phy-
sical examination, vital signs. The results of primary efficacy 
variable will be reported by means of default descriptive 
statistics. Change of CAT score from the start of treatment 
with BDP/FF/G (retrospective data) to endpoint (Month 12 
or early withdrawal) will be calculated with the two-sided 95% 
CI. The change of CAT over the study will be analyzed by 
means of the analysis of variance for repeated measures. The 
results of secondary efficacy variables will be reported by 
means of default descriptive statistics. For continuous vari-
ables, the two-sided 95% CI for changes from start of treatment 
with BDP/FF/G (retrospective data) for CAT and pulmonary 
function tests, and for changes from baseline (Visit 1) for the 
other secondary efficacy variables, to Month 6 and Month 12 
(or early withdrawal) will be calculated. The change in sec-
ondary efficacy continuous variables over the study will be 
analyzed by means of the analysis of variance for repeated 
measures. Means with their 95% confidence interval will be 
presented at each study timepoint. Categorical endpoints (ie, 
proportion of patients with moderate and severe COPD exacer-
bations during the overall observational period) will be pre-
sented using counts of patients, percentages with 95% 
confidence interval. Analysis by subgroups (eg, gender, age 
range, COPD severity range or any other subgroup that will be 
considered of clinical relevance) of primary and secondary 
efficacy variables will be performed by descriptive statistics 
provided that the distribution in size of subgroups will be 
adequately balanced. Comparison between/among subgroups 
might be investigated using the propensity score methodology, 
depending on the actual number of patients in the subgroups. 
Regression analysis may be used to assess the association of 
any factor/covariate and the primary efficacy endpoint.
Discussion
TRITRIAL study will collect information on the effect of 
treatment with BDP/FF/G on health status, HRQoL and adher-
ence to therapy, to gather knowledge from routine care on 
whether a fixed triple therapy with a single inhaler will lead 
to relevant changes in disease-related outcomes, based on the 
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available evidence that triple therapy determines an improve-
ment in COPD patients not controlled by maintenance treat-
ment. The primary goals of COPD therapy21 are the prevention 
of future risks (exacerbations or clinical deterioration) and the 
reduction of symptoms, including improvement of health sta-
tus. In line with these recommendations, the BDP/FF/G clin-
ical program provided evidence for clinical benefits for a fixed 
triple therapy using a single pMDI compared to current stan-
dard therapies, supporting the rationale for a step-up approach 
in clinical practice. Despite the fact that improvement in both 
symptoms and health status is an objective of COPD treatment, 
the assessment of symptoms is not always adequate to drive the 
choice of therapy and the measurement of health status may 
require the use of complex assessment tools. TRITRIAL study 
will provide a reliable assessment of health status using CAT 
score as primary objective. CAT score can easily be used in 
daily clinical practice to quantify the impact of COPD symp-
toms on the risk of developing serious exacerbations, and thus 
may help in a clinical setting to match the patient’s therapy 
more closely to individual needs. CAT score is also included in 
the combined COPD assessment indicated by GOLD recom-
mendations. As the CAT is an instrument that measures not 
only the respiratory symptom burden of COPD, but also the 
general health status of patients in daily practice (ie, lack of 
energy or sleep disturbances, limitations in doing activities at 
home or confidence leaving home), it can be considered as 
a measure of HRQoL in general. Furthermore, recent studies 
have shown that the use of multiple inhalers and mixed inhala-
tion techniques increase the risk of exacerbations compared to 
COPD patients using single inhalers or multiple inhalers 
requiring the same inhalation technique.24,25 The selection of 
a single inhaler could be beneficial to adherence and treatment 
effectiveness, which are also endpoints of the study. There is 
evidence supporting the association between inhaler satisfac-
tion and patient adherence, as well as improved clinical out-
come. Patients who use their preferred inhaler device may 
obtain a greater degree of satisfaction with therapy, and it is 
well established that COPD patients are more likely to be 
compliant and to experience better outcomes when they are 
satisfied with their inhalers.26 We chose to evaluate patients 
receiving therapy with the fixed BDP/FF/G combination for 
several reasons: it was the first fixed triple therapy available for 
prescription and it has been used in clinical practice for more 
than a year; it is the only extrafine-particle fixed triple therapy, 
which is suitable for treating small airway dysfunction in 
COPD patients,7 a respiratory tract that is related to high 
impact of disease on health status (as measured by CAT)12 
and quality of sleep (as measured by CASIS);14 it is the only 
twice-daily fixed triple and it could also be beneficial in 
patients with high burden of morning and night-time 
symptoms.27 In TRITRIAL study, adherence and device 
usability evaluation, based on validated questionnaires’ scores, 
will be crucial to better understand how fixed triple therapy in 
a single inhaler could impact on these aspects of the disease. 
Furthermore, this study will collect data on economic resources 
consumption over a one-year treatment period with fixed triple 
therapy, as a secondary variable. In fact, the effectiveness of 
BDP/FF/G in reducing exacerbations, and in improving 
HRQoL and disease-related variables may positively impact 
on healthcare costs, eg, in terms of decrease of hospitalizations, 
emergency room attendance, further unscheduled healthcare 
visits and examinations, and prescription of therapy to treat 
worsening of COPD. Overall, TRITRIAL study is expected to 
give consistent information about efficacy of fixed triple ther-
apy with BDP/FF/G in a real life setting of patients with 
COPD, where adherence and other variables associated with 
the individual subject are crucial factors for the success of the 
therapy.
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